Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

NH2-terminal pro-brain natriuretic peptide and risk of diabetes.

Lazo M, Young JH, Brancati FL, Coresh J, Whelton S, Ndumele CE, Hoogeveen R, Ballantyne CM, Selvin E.

Diabetes. 2013 Sep;62(9):3189-93. doi: 10.2337/db13-0478. Epub 2013 Jun 3.

2.

Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors.

Luchner A, Behrens G, Stritzke J, Markus M, Stark K, Peters A, Meisinger C, Leitzmann M, Hense HW, Schunkert H, Heid IM.

Eur J Heart Fail. 2013 Aug;15(8):859-67. doi: 10.1093/eurjhf/hft048. Epub 2013 Apr 7.

3.

N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study.

Bower JK, Lazo M, Matsushita K, Rubin J, Hoogeveen RC, Ballantyne CM, Selvin E.

Am J Hypertens. 2015 Oct;28(10):1262-6. doi: 10.1093/ajh/hpv026. Epub 2015 Mar 16.

4.

Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study.

Brutsaert EF, Biggs ML, Delaney JA, Djoussé L, Gottdiener JS, Ix JH, Kim F, Mukamal KJ, Siscovick DS, Tracy RP, de Boer IH, deFilippi CR, Kizer JR.

Metabolism. 2016 Oct;65(10):1489-97. doi: 10.1016/j.metabol.2016.06.002. Epub 2016 Jun 24.

5.

Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study.

Kim Y, Matsushita K, Sang Y, Grams ME, Skali H, Shah AM, Hoogeveen RC, Solomon SD, Ballantyne CM, Coresh J.

Am J Kidney Dis. 2015 Apr;65(4):550-8. doi: 10.1053/j.ajkd.2014.08.021. Epub 2014 Oct 23.

6.

A cross sectional study comparing traditional risk factors with N-terminal pro-BNP in high risk groups for cardiovascular disease in Trinidad, West Indies.

Shivananda Nayak B, Teelucksingh S, Jagessar A, Maharaj S, Maharaj N.

Diabetes Metab Syndr. 2013 Jan-Mar;7(1):8-11. doi: 10.1016/j.dsx.2013.02.021. Epub 2013 Mar 7.

PMID:
23517788
7.

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P.

JAMA. 2005 Apr 6;293(13):1609-16.

PMID:
15811980
8.

N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study.

Singh HS, Bibbins-Domingo K, Ali S, Wu AH, Schiller NB, Whooley MA.

Clin Cardiol. 2009 Aug;32(8):447-53. doi: 10.1002/clc.20569.

9.

N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama study.

Doi Y, Ninomiya T, Hata J, Hirakawa Y, Mukai N, Ikeda F, Fukuhara M, Iwase M, Kiyohara Y.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2997-3003. doi: 10.1161/ATVBAHA.111.223669. Epub 2011 Sep 15.

11.

N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study.

März W, Tiran B, Seelhorst U, Wellnitz B, Bauersachs J, Winkelmann BR, Boehm BO; LURIC Study Team.

Clin Chem. 2007 Jun;53(6):1075-83. Epub 2007 Apr 19.

12.

Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.

Ahluwalia N, Blacher J, Szabo de Edelenyi F, Faure P, Julia C, Hercberg S, Galan P.

Atherosclerosis. 2013 Jun;228(2):478-84. doi: 10.1016/j.atherosclerosis.2013.03.017. Epub 2013 Mar 26.

PMID:
23582589
13.

Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile.

Neeland IJ, Winders BR, Ayers CR, Das SR, Chang AY, Berry JD, Khera A, McGuire DK, Vega GL, de Lemos JA, Turer AT.

J Am Coll Cardiol. 2013 Aug 20;62(8):752-60. doi: 10.1016/j.jacc.2013.03.038. Epub 2013 Apr 16.

14.

Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals.

Cheng S, Fox CS, Larson MG, Massaro JM, McCabe EL, Khan AM, Levy D, Hoffmann U, O'Donnell CJ, Miller KK, Newton-Cheh C, Coviello AD, Bhasin S, Vasan RS, Wang TJ.

Am J Cardiol. 2011 Oct 1;108(7):979-84. doi: 10.1016/j.amjcard.2011.05.033. Epub 2011 Aug 1.

15.
16.
17.

Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study.

Park M, Vittinghoff E, Shlipak MG, Mishra R, Whooley M, Bansal N.

Am Heart J. 2014 Dec;168(6):931-9.e2. doi: 10.1016/j.ahj.2014.09.008. Epub 2014 Oct 14.

18.

Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr.

J Am Coll Cardiol. 2006 Jan 17;47(2):345-53. Epub 2006 Jan 4.

19.

A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus.

Clodi M, Resl M, Neuhold S, Hülsmann M, Vila G, Elhenicky M, Strunk G, Abrahamian H, Prager R, Luger A, Pacher R.

Eur J Prev Cardiol. 2012 Oct;19(5):944-51. doi: 10.1177/1741826711420015. Epub 2011 Aug 19.

PMID:
21856715
20.

Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.

Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr.

Am Heart J. 2005 Apr;149(4):744-50.

PMID:
15990762

Supplemental Content

Support Center